{"id":36748,"title":"Mild Hypothermia to prevent Acute kidney injury in Liver Transplantation (MHALT) Trial - Statistical Analysis Plan for the Interim Analysis, v1.0 ","title_html":"<p>Mild Hypothermia to prevent Acute kidney injury in Liver Transplantation (MHALT) Trial - Statistical Analysis Plan for the Interim Analysis, v1.0 <\/p>","image":{"source":"https:\/\/s3.amazonaws.com\/protocols-files\/public\/c0e6a0ea0cd4c875b468134852c079179b231b3b07da8820895642c70e00b43c\/b7y79efw.jpg","placeholder":"https:\/\/s3.amazonaws.com\/protocols-files\/public\/c0e6a0ea0cd4c875b468134852c079179b231b3b07da8820895642c70e00b43c\/b7y79efw.jpg"},"doi":"dx.doi.org\/10.17504\/protocols.io.bf5kjq4w","doi_status":2,"uri":"mild-hypothermia-to-prevent-acute-kidney-injury-in-bf5kjq4w","type_id":1,"published_on":1588892371,"parent_protocols":[],"parent_collections":[],"cited_protocols":[],"version_id":0,"created_on":1588862754,"categories":null,"creator":{"name":"Michael Bokoch","affiliation":"University of California, San Francisco","affiliations":[{"affiliation":"University of California, San Francisco","url":"https:\/\/anesthesia.ucsf.edu\/","is_default":1}],"username":"michael-bokoch","link":null,"image":{"source":"https:\/\/s3.amazonaws.com\/protocols-files\/public\/c0e6a0ea0cd4c875b468134852c079179b231b3b07da8820895642c70e00b43c\/brrw9efw.jpg","placeholder":"https:\/\/s3.amazonaws.com\/protocols-files\/public\/c0e6a0ea0cd4c875b468134852c079179b231b3b07da8820895642c70e00b43c\/brrw9efw.jpg"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"}],"verified":0,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"journal":null,"journal_name":null,"journal_link":null,"article_citation":null,"public":1,"has_versions":0,"link":"","total_collections":0,"number_of_steps":9,"authors":[{"name":"Michael Bokoch","affiliation":"University of California, San Francisco","affiliations":[],"username":"michael-bokoch","link":null,"image":{"source":"https:\/\/s3.amazonaws.com\/protocols-files\/public\/c0e6a0ea0cd4c875b468134852c079179b231b3b07da8820895642c70e00b43c\/brrw9efw.jpg","placeholder":"https:\/\/s3.amazonaws.com\/protocols-files\/public\/c0e6a0ea0cd4c875b468134852c079179b231b3b07da8820895642c70e00b43c\/brrw9efw.jpg"},"badges":[],"verified":1,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Claus Niemann","affiliation":"University of California, San Francisco","affiliations":[],"username":"claus-niemann","link":null,"image":{"source":"\/img\/avatars\/015.png","placeholder":"\/img\/avatars\/015.png"},"badges":[],"verified":1,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Dieter Adelmann","affiliation":"University of California, San Francisco","affiliations":[],"username":"dieter-adelmann","link":null,"image":{"source":"\/img\/avatars\/017.png","placeholder":"\/img\/avatars\/017.png"},"badges":[],"verified":1,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Rishi Kothari","affiliation":"University of California, San Francisco","affiliations":[],"username":"rishi-kothari","link":null,"image":{"source":"\/img\/avatars\/005.png","placeholder":"\/img\/avatars\/005.png"},"badges":[],"verified":1,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false}],"versions":[],"groups":[{"id":1348,"uri":"ucsf-transplant-anesthesia-research-group-targ","title":"UCSF Transplant Anesthesia Research Group (TARG)","image":{"source":"https:\/\/www.protocols.io\/img\/group_placeholder.png","placeholder":"https:\/\/www.protocols.io\/img\/group_placeholder.png"},"tech_support":{"email":null,"phone":null,"hide_contact":0,"use_email":0,"url":null},"is_member":1,"request":{"id":1348,"uri":"ucsf-transplant-anesthesia-research-group-targ","title":"UCSF Transplant Anesthesia Research Group (TARG)","image":{"source":"https:\/\/www.protocols.io\/img\/group_placeholder.png","placeholder":"https:\/\/www.protocols.io\/img\/group_placeholder.png"},"tech_support":{"email":null,"phone":null,"hide_contact":0,"use_email":0,"url":null},"is_member":1,"description":null,"research_interests":null,"website":null,"location":null,"affiliation":null,"status":{"is_visible":true,"access_level":0},"stats":{"files":[],"total_members":0,"total_followers":0,"total_child_groups":0,"total_parent_groups":0,"has_collaborations":0},"user_status":{"is_member":true,"is_confirmed":true,"is_invited":false,"is_owner":true,"is_admin":false,"is_following":false},"join_link":null,"token":null,"owner":{"name":" ","affiliation":null,"affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"is_protocol_requested":0,"is_group_requested":0,"is_my":false,"is_request":false,"is_confirmed":1,"is_declined":0,"requester":{"name":" ","affiliation":null,"affiliation_url":null,"username":null,"link":null},"protocol":{"id":0,"title":"Mild Hypothermia to prevent Acute kidney injury in Liver Transplantation (MHALT) Trial - Statistical Analysis Plan for the Interim Analysis, v1.0 ","title_html":"Mild Hypothermia to prevent Acute kidney injury in Liver Transplantation (MHALT) Trial - Statistical Analysis Plan for the Interim Analysis, v1.0 ","image":{"source":null,"placeholder":null},"doi":null,"doi_status":0,"uri":"mild-hypothermia-to-prevent-acute-kidney-injury-in-bf5kjq4w","type_id":1,"published_on":null,"stats":{"number_of_views":0,"number_of_steps":0,"number_of_bookmarks":0,"number_of_comments":0,"number_of_exports":0,"number_of_runs":0,"number_of_votes":0,"is_voted":0},"parent_protocols":[],"parent_collections":[],"cited_protocols":[]},"created_on":1588892178,"resolve_on":0,"resolved_user":{"name":" ","affiliation":null,"affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"shared":false}}],"is_owner":1,"has_subprotocols":0,"is_subprotocol":0,"is_bookmarked":1,"can_claim_authorship":0,"can_accept_authorship":0,"can_be_copied":1,"can_remove_fork":1,"fork_id":null,"url":"https:\/\/www.protocols.io\/view\/mild-hypothermia-to-prevent-acute-kidney-injury-in-bf5kjq4w","forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":1,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"guid":"61A57900907111EABB02AF64BF121A7F","state_version_id":505,"steps":[{"id":935374,"guid":"25A938A0907211EABB02AF64BF121A7F","previous_id":null,"previous_guid":null,"modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"9C6A91EBFCD54614B7512D8E4FED6EE9","order_id":1,"type_id":6,"title":"Section","source":{"title":"STATISTICAL CONSIDERATIONS"}},{"id":1054724,"guid":"35E198AD36154345AFAC2FC6D23C3106","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span style = \"font-weight:bold;\">Statistical Analysis Plan for the Interim Analysis<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><\/div><\/div><div class = \"text-block\"><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03534141\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">NCT03534141<\/span><\/a><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\">UCSF IRB # 17-22384<\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\">Version 1.0<\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\">May 7, 2020<\/div><\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#A492FF","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":935378,"guid":"56E3C2A0907211EABB02AF64BF121A7F","previous_id":935374,"previous_guid":"25A938A0907211EABB02AF64BF121A7F","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"730A4B6D828B4E37BEC12E21553189A0","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"4A3BA348EE604D53B90FC07A8897CC17","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Analysis Populations<\/span><\/div><div class = \"text-block\">The following populations will be used for the summaries and analyses of the study data. These populations are defined as follows:<\/div><div class = \"text-block\"><ul style = \"list-style-type:disc;\"><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Randomized:<\/span><span>The Randomized population will consist of all subjects who are randomized to a treatment group<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Intention-to-treat (ITT):<\/span><span>The ITT population will consist of all randomized subjects not withdrawn from the study. The interim efficacy analysis will be based on the ITT population.<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Per-Protocol (PP):<\/span><span>The PP population will consist of all ITT subjects who complete liver transplant, received the full randomized study treatment, and complete 72 hours of study follow up. Analyses of the PP population will be performed in the final statistical analysis.<\/span><\/li><\/ul><\/div><div class = \"text-block\"><ul style = \"list-style-type:disc;\"><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Intention-to-treat (ITT):<\/span><span>The ITT population will consist of all randomized subjects not withdrawn from the study. The interim efficacy analysis will be based on the ITT population.<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Per-Protocol (PP):<\/span><span>The PP population will consist of all ITT subjects who complete liver transplant, received the full randomized study treatment, and complete 72 hours of study follow up. Analyses of the PP population will be performed in the final statistical analysis.<\/span><\/li><\/ul><\/div><div class = \"text-block\"><ul style = \"list-style-type:disc;\"><\/ul><\/div><div class = \"text-block\">Adjustments may be made to refine the definition of the above populations prior to database lock for the final statistical analysis. The final definition of these populations will be documented in a prospectively developed final statistical analysis plan (final SAP) published on Protocols.io. The final SAP must be finalized and approved prior to database lock and unblinding.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":935658,"guid":"82B50320909111EAAAA2CDB4FD66F056","previous_id":935378,"previous_guid":"56E3C2A0907211EABB02AF64BF121A7F","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"BEB5889CA5DB408AB3DDAA57E83AD255","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"C23D84F76F774D089961A026C9E8B800","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Statistical Hypotheses<\/span><\/div><div class = \"text-block\"><span>The null (H<\/span><span style = \"vertical-align:sub;\">0<\/span><span>) hypothesis and the alternative (H<\/span><span style = \"vertical-align:sub;\">1<\/span><span>) hypothesis to be tested for the primary endpoint are that:<\/span><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span style = \"vertical-align:sub;\">H<\/span><span style = \"vertical-align:sub;\">0<\/span><span>: <\/span><span style = \"vertical-align:sub;font-style:italic;\">p<\/span><span style = \"vertical-align:sub;\">1 <\/span><span style = \"font-style:italic;\">= p<\/span><span style = \"vertical-align:sub;font-style:italic;\">2<\/span><span> versus H<\/span><span style = \"vertical-align:sub;\">1<\/span><span>: <\/span><span style = \"vertical-align:sub;font-style:italic;\">p<\/span><span style = \"vertical-align:sub;\">1 <\/span><span style = \"vertical-align:sub;vertical-align:sub;\">\u2260<\/span><span style = \"vertical-align:sub;font-style:italic;\"> <\/span><span style = \"vertical-align:sub;vertical-align:sub;font-style:italic;\">p<\/span><span style = \"vertical-align:sub;font-style:italic;\">2<\/span><span><\/span><\/div><\/div><div class = \"text-block\"><span>Where <\/span><span style = \"font-style:italic;vertical-align:sub;\">p<\/span><span style = \"font-style:italic;vertical-align:sub;\">1<\/span><span> is the proportion of the ITT population meeting the primary outcome in the Control Arm (Normothermia), and <\/span><span style = \"font-style:italic;vertical-align:sub;\">p<\/span><span style = \"font-style:italic;vertical-align:sub;\">2<\/span><span> is the proportion of the ITT population meeting the primary outcome in the Experimental Treatment Arm (Mild Hypothermia).<\/span><\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":935659,"guid":"C3F54430909111EAAAA2CDB4FD66F056","previous_id":935658,"previous_guid":"82B50320909111EAAAA2CDB4FD66F056","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"60D6B2E84E274FCBB22734E90A9FE9BD","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"C139A05FCD9F4E0C98E36D8966641ABE","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Demographic and Baseline Characteristics<\/span><\/div><div class = \"text-block\">For the final statistical analysis, demographic and relevant baseline characteristics will be presented and summarized descriptively by treatment for the Randomized, ITT, and the PP populations. These characteristics will not be included for the interim statistical analysis for efficacy, as they have been summarized and reported elsewhere to the Data Safety Monitoring Board (DSMB). Additional summary of demographic and baseline characteristics may be specified in the final SAP, if deemed necessary.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":935730,"guid":"F604F880909111EAAAA2CDB4FD66F056","previous_id":935659,"previous_guid":"C3F54430909111EAAAA2CDB4FD66F056","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"E4EC3893A3D14F80812CEA766F12D4EA","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"5912C14FC2E645A0A9EC8DBFB7852AE9","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Sample Size Justification and Power Analysis<\/span><\/div><div class = \"text-block\"><span>Considering one interim analysis for efficacy, and given the incidence of acute kidney injury (AKI) in liver transplantation (LTx) patients at UCSF (68%), we estimate a sample size of 101 subjects per arm (<\/span><span style = \"font-style:italic;\">n<\/span><span> = 202 total) is needed to detect a 30% reduction in AKI with 80% power at overall alpha = 0.05 (two-tailed).<\/span><\/div><div class = \"text-block\">We will aim to enroll 230 total subjects to allow for just over a 10% drop-out rate, since some subjects may not be able to complete the protocol and be withdrawn from the study.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":935731,"guid":"16C38A00909211EAAAA2CDB4FD66F056","previous_id":935730,"previous_guid":"F604F880909111EAAAA2CDB4FD66F056","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"067A6F430FA248FDB8D24D82A46F8C63","order_id":1,"type_id":6,"title":"Section","source":{"title":"STATISTICAL ANALYSES"}},{"id":1054724,"guid":"7292C82453034922956350640EB581C6","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-style:italic;\">1.5.1. Interim Analysis for Efficacy<\/span><\/div><div class = \"text-block\"><span>A single interim analysis for efficacy is planned for this study after 50% of the required patients (101 of the 202 estimated by the power calculation) are accrued after accounting for withdrawn subjects. Based on the O'Brien-Fleming approach to calculate alpha spending, during the interim analysis step, if the <\/span><span style = \"font-style:italic;\">p<\/span><span> value is < 0.0054, the study will be stopped as the desired efficacy will have been achieved; if not, then we will continue the study. If the final <\/span><span style = \"font-style:italic;\">p<\/span><span> value after 100% enrollment is < 0.0492, then we will declare that the AKI status is different between the two arms.<\/span><\/div><div class = \"text-block\"><span style = \"font-style:italic;\">1.5.2. Analyses of Primary Efficacy Endpoint<\/span><span>\u0394<\/span><\/div><div class = \"text-block\">The primary efficacy endpoint is the incidence of AKI within 72 hours after LTx. The International Club for Ascites (ICA) 2015 criteria, a revision of the Kidney Disease Improving Global Outcomes (KDIGO) criteria for patients with cirrhosis, will be used to define AKI (Angeli et al., 2015). The definitions are as follows:<\/div><div class = \"text-block\"><ul style = \"list-style-type:disc;\"><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">AKI<\/span><span>: increase in serum creatinine (sCr) \u2265 0.3 mg\/dL within a 48-hour time window, or a percentage increase \u2265 50% from baseline, or initiation of renal replacement therapy (RRT)<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Baseline sCr<\/span><span>: the most recent value of sCr prior to LTx<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">The primary outcome (presence or absence AKI) will be compared between the two arms by a two-sample test of proportions (Fisher\u2019s exact test or chi-square, as appropriate).<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">To determine whether a subject met the primary outcome, the following procedure is followed in order:<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Step #1. Need for renal replacement therapy <\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">If the patient had RRT within 72 hrs from the End of Surgery (\u201cpostop_rrt_72h\u201d = yes), the primary outcome is met (subject had AKI).<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Step #2. Calculation of the fold-increase in sCr<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">The interim analysis database will contain four sCr values:<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>a. <\/span><span style = \"font-weight:bold;\">creat_0 = <\/span><span>Baseline sCr (most recent prior to Surgery)<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>b. <\/span><span style = \"font-weight:bold;\">creat_24h<\/span><span> = Highest sCr, 0-24 hrs from End of Surgery<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>c. <\/span><span style = \"font-weight:bold;\">creat_48h<\/span><span> = Highest sCr, 24-48 hrs from End of Surgery<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>d. <\/span><span style = \"font-weight:bold;\">creat_72h<\/span><span> = Highest sCr, 48-72 hrs from End of Surgery<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>The highest of these values (<\/span><span style = \"font-style:italic;\">b-d<\/span><span>) will be used to calculate the following:<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><a href=\"#\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> <\/span><\/a><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">If the Fold increase in sCr is \u2265 1.5, the primary outcome is met (subject had AKI).<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Step #3.Calculation of the difference in sCr<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">The following calculation should be performed:<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><a href=\"#\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> <\/span><\/a><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If \u0394sCr<\/span><span style = \"vertical-align:sub;\">max <\/span><span>< 0.3 mg\/dL, the primary outcome is NOT met (subject DOES NOT have AKI).<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If \u0394sCr<\/span><span style = \"vertical-align:sub;\">max <\/span><span>\u2265 0.3 mg\/dL, but the patient does not meet either of the criteria described in <\/span><span style = \"font-weight:bold;\">Step #1 (RRT)<\/span><span> or <\/span><span style = \"font-weight:bold;\">Step #2 (Fold increase)<\/span><span>, additional timing information may be required to determine if the subject had AKI. According to KDIGO criteria, the sCr must increase by \u2265 0.3 mg\/dL within a 48 hour time window to diagnose AKI (i.e., if the sCr increased by 0.3 mg\/dL over 72 h, this is not necessarily AKI) (Kellum et al., 2012). In this situation, the following calculations should be performed:<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><a href=\"#\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> <\/span><\/a><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">* indicates a time interval that is unambiguous (definitively less than 48 h)<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If either \u0394<\/span><span style = \"vertical-align:sub;\">3<\/span><span> or \u0394<\/span><span style = \"vertical-align:sub;\">5<\/span><span> is \u2265 0.3 mg\/dL, the timing is unambiguous (< 48 h window). The primary outcome is met (subject has AKI).<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If any of \u0394<\/span><span style = \"vertical-align:sub;\">1<\/span><span>, \u0394<\/span><span style = \"vertical-align:sub;\">2<\/span><span>, or \u0394<\/span><span style = \"vertical-align:sub;\">4<\/span><span> is \u2265 0.3 mg\/dL, the timing is ambiguous and further information is required to determine AKI status. The Data Management Team will provide the Statistician with the exact times and dates of collection for the relevant sCr values. <\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>The time interval (\u0394<\/span><span style = \"font-style:italic;\">t<\/span><span>) between sCr collections should be calculated for each \u0394<\/span><span style = \"vertical-align:sub;\">1, 2, or 4 <\/span><span>that is \u2265 0.3 mg\/dL. <\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If any \u0394<\/span><span style = \"font-style:italic;\">t<\/span><span> is \u2264 48 h, the primary outcome is met (subject has AKI).<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If all \u0394<\/span><span style = \"font-style:italic;\">t<\/span><span> > 48 h, the primary outcome is NOT met (subject DOES NOT have AKI).<\/span><\/li><\/ul><\/div><div class = \"text-block\"><ul style = \"list-style-type:disc;\"><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Baseline sCr<\/span><span>: the most recent value of sCr prior to LTx<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">The primary outcome (presence or absence AKI) will be compared between the two arms by a two-sample test of proportions (Fisher\u2019s exact test or chi-square, as appropriate).<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">To determine whether a subject met the primary outcome, the following procedure is followed in order:<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Step #1. Need for renal replacement therapy <\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">If the patient had RRT within 72 hrs from the End of Surgery (\u201cpostop_rrt_72h\u201d = yes), the primary outcome is met (subject had AKI).<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Step #2. Calculation of the fold-increase in sCr<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">The interim analysis database will contain four sCr values:<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>a. <\/span><span style = \"font-weight:bold;\">creat_0 = <\/span><span>Baseline sCr (most recent prior to Surgery)<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>b. <\/span><span style = \"font-weight:bold;\">creat_24h<\/span><span> = Highest sCr, 0-24 hrs from End of Surgery<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>c. <\/span><span style = \"font-weight:bold;\">creat_48h<\/span><span> = Highest sCr, 24-48 hrs from End of Surgery<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>d. <\/span><span style = \"font-weight:bold;\">creat_72h<\/span><span> = Highest sCr, 48-72 hrs from End of Surgery<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>The highest of these values (<\/span><span style = \"font-style:italic;\">b-d<\/span><span>) will be used to calculate the following:<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><a href=\"#\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> <\/span><\/a><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">If the Fold increase in sCr is \u2265 1.5, the primary outcome is met (subject had AKI).<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span style = \"font-weight:bold;\">Step #3.Calculation of the difference in sCr<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">The following calculation should be performed:<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><a href=\"#\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> <\/span><\/a><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If \u0394sCr<\/span><span style = \"vertical-align:sub;\">max <\/span><span>< 0.3 mg\/dL, the primary outcome is NOT met (subject DOES NOT have AKI).<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If \u0394sCr<\/span><span style = \"vertical-align:sub;\">max <\/span><span>\u2265 0.3 mg\/dL, but the patient does not meet either of the criteria described in <\/span><span style = \"font-weight:bold;\">Step #1 (RRT)<\/span><span> or <\/span><span style = \"font-weight:bold;\">Step #2 (Fold increase)<\/span><span>, additional timing information may be required to determine if the subject had AKI. According to KDIGO criteria, the sCr must increase by \u2265 0.3 mg\/dL within a 48 hour time window to diagnose AKI (i.e., if the sCr increased by 0.3 mg\/dL over 72 h, this is not necessarily AKI) (Kellum et al., 2012). In this situation, the following calculations should be performed:<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><a href=\"#\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\"> <\/span><\/a><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\">* indicates a time interval that is unambiguous (definitively less than 48 h)<\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If either \u0394<\/span><span style = \"vertical-align:sub;\">3<\/span><span> or \u0394<\/span><span style = \"vertical-align:sub;\">5<\/span><span> is \u2265 0.3 mg\/dL, the timing is unambiguous (< 48 h window). The primary outcome is met (subject has AKI).<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If any of \u0394<\/span><span style = \"vertical-align:sub;\">1<\/span><span>, \u0394<\/span><span style = \"vertical-align:sub;\">2<\/span><span>, or \u0394<\/span><span style = \"vertical-align:sub;\">4<\/span><span> is \u2265 0.3 mg\/dL, the timing is ambiguous and further information is required to determine AKI status. The Data Management Team will provide the Statistician with the exact times and dates of collection for the relevant sCr values. <\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>The time interval (\u0394<\/span><span style = \"font-style:italic;\">t<\/span><span>) between sCr collections should be calculated for each \u0394<\/span><span style = \"vertical-align:sub;\">1, 2, or 4 <\/span><span>that is \u2265 0.3 mg\/dL. <\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If any \u0394<\/span><span style = \"font-style:italic;\">t<\/span><span> is \u2264 48 h, the primary outcome is met (subject has AKI).<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If all \u0394<\/span><span style = \"font-style:italic;\">t<\/span><span> > 48 h, the primary outcome is NOT met (subject DOES NOT have AKI).<\/span><\/li><\/ul><\/div><div class = \"text-block\">The primary outcome (presence or absence AKI) will be compared between the two arms by a two-sample test of proportions (Fisher\u2019s exact test or chi-square, as appropriate).<\/div><div class = \"text-block\">To determine whether a subject met the primary outcome, the following procedure is followed in order:<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Step #1. Need for renal replacement therapy <\/span><\/div><div class = \"text-block\">If the patient had RRT within 72 hrs from the End of Surgery (\u201cpostop_rrt_72h\u201d = yes), the primary outcome is met (subject had AKI).<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Step #2. Calculation of the fold-increase in sCr<\/span><\/div><div class = \"text-block\">The interim analysis database will contain four sCr values:<\/div><div class = \"text-block\"><span>a. <\/span><span style = \"font-weight:bold;\">creat_0 = <\/span><span>Baseline sCr (most recent prior to Surgery)<\/span><\/div><div class = \"text-block\"><span>b. <\/span><span style = \"font-weight:bold;\">creat_24h<\/span><span> = Highest sCr, 0-24 hrs from End of Surgery<\/span><\/div><div class = \"text-block\"><span>c. <\/span><span style = \"font-weight:bold;\">creat_48h<\/span><span> = Highest sCr, 24-48 hrs from End of Surgery<\/span><\/div><div class = \"text-block\"><span>d. <\/span><span style = \"font-weight:bold;\">creat_72h<\/span><span> = Highest sCr, 48-72 hrs from End of Surgery<\/span><\/div><div class = \"text-block\"><span>The highest of these values (<\/span><span style = \"font-style:italic;\">b-d<\/span><span>) will be used to calculate the following:<\/span><\/div><div class = \"text-block\"><pre><code><div class = \"text-blocks\"><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\">Fold increase in sCr = Maximum of {creat_24h, creat_48h, creat_72h} \/ creat_0<\/div><\/div><\/div><\/code><\/pre><\/div><div class = \"text-block\">If the Fold increase in sCr is \u2265 1.5, the primary outcome is met (subject had AKI).<\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Step #3.Calculation of the difference in sCr<\/span><\/div><div class = \"text-block\">The following calculation should be performed:<\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><\/div><\/div><div class = \"text-block\"><pre><code><div class = \"text-blocks\"><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span>\u0394sCr<\/span><span style = \"vertical-align:sub;\">max<\/span><span> = Maximum of {creat_24h, creat_48h, creat_72h} \u2013 <\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\">Minimum of {creat_0, creat_24h, creat_48h}<\/div><\/div><\/div><\/code><\/pre><\/div><div class = \"text-block\"><span>If \u0394sCr<\/span><span style = \"vertical-align:sub;\">max <\/span><span>< 0.3 mg\/dL, the primary outcome is NOT met (subject DOES NOT have AKI).<\/span><\/div><div class = \"text-block\"><span>If \u0394sCr<\/span><span style = \"vertical-align:sub;\">max <\/span><span>\u2265 0.3 mg\/dL, but the patient does not meet either of the criteria described in <\/span><span style = \"font-weight:bold;\">Step #1 (RRT)<\/span><span> or <\/span><span style = \"font-weight:bold;\">Step #2 (Fold increase)<\/span><span>, additional timing information may be required to determine if the subject had AKI. According to KDIGO criteria, the sCr must increase by \u2265 0.3 mg\/dL within a 48 hour time window to diagnose AKI (i.e., if the sCr increased by 0.3 mg\/dL over 72 h, this is not necessarily AKI) (Kellum et al., 2012). In this situation, the following calculations should be performed:<\/span><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><\/div><\/div><div class = \"text-block\"><pre><code><div class = \"text-blocks\"><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span style = \"vertical-align:sub;\">\u0394<\/span><span style = \"vertical-align:sub;\">1<\/span><span> = creat_24h \u2013 creat_0<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span style = \"vertical-align:sub;\">\u0394<\/span><span style = \"vertical-align:sub;\">2<\/span><span> = creat_48h \u2013 creat_0<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span>*\u0394<\/span><span style = \"vertical-align:sub;\">3<\/span><span> = creat_48h \u2013 creat_24h<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span style = \"vertical-align:sub;\">\u0394<\/span><span style = \"vertical-align:sub;\">4<\/span><span> = creat_72h \u2013 creat_24h<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:center\"><span>*\u0394<\/span><span style = \"vertical-align:sub;\">5<\/span><span> = creat_72h \u2013 creat_48h<\/span><\/div><\/div><\/div><\/code><\/pre><\/div><div class = \"text-block\">* indicates a time interval that is unambiguous (definitively less than 48 h)<\/div><div class = \"text-block\"><span>If either \u0394<\/span><span style = \"vertical-align:sub;\">3<\/span><span> or \u0394<\/span><span style = \"vertical-align:sub;\">5<\/span><span> is \u2265 0.3 mg\/dL, the timing is unambiguous (< 48 h window). The primary outcome is met (subject has AKI).<\/span><\/div><div class = \"text-block\"><span>If any of \u0394<\/span><span style = \"vertical-align:sub;\">1<\/span><span>, \u0394<\/span><span style = \"vertical-align:sub;\">2<\/span><span>, or \u0394<\/span><span style = \"vertical-align:sub;\">4<\/span><span> is \u2265 0.3 mg\/dL, the timing is ambiguous and further information is required to determine AKI status. The Data Management Team will provide the Statistician with the exact times and dates of collection for the relevant sCr values. <\/span><\/div><div class = \"text-block\"><ul style = \"list-style-type:disc;\"><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>The time interval (\u0394<\/span><span style = \"font-style:italic;\">t<\/span><span>) between sCr collections should be calculated for each \u0394<\/span><span style = \"vertical-align:sub;\">1, 2, or 4 <\/span><span>that is \u2265 0.3 mg\/dL. <\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If any \u0394<\/span><span style = \"font-style:italic;\">t<\/span><span> is \u2264 48 h, the primary outcome is met (subject has AKI).<\/span><\/li><li style = \"counter-reset:ol0;list-style-type:disc;\"><span>If all \u0394<\/span><span style = \"font-style:italic;\">t<\/span><span> > 48 h, the primary outcome is NOT met (subject DOES NOT have AKI).<\/span><\/li><\/ul><\/div><div class = \"text-block\"><span style = \"font-weight:bold;\">Step #4. Death of a subject prior to 72 hours from the End of Surgery<\/span><\/div><div class = \"text-block\">If a subject died < 72 h from the end of surgery, the subject is defined as having met the primary outcome (subject has AKI). This agrees with the definition of Major Adverse Kidney Events recommended for clinical trials (Kellum et al., 2017).<\/div><div class = \"text-block\"><span style = \"font-style:italic;\">1.5.3. Analyses of Secondary Endpoints<\/span><\/div><div class = \"text-block\">Analyses of secondary endpoints are not included in the interim analysis for this study. A detailed analysis of the frequencies and distribution of KDIGO stages of AKI is an important component of the final statistical analysis.<\/div><div class = \"text-block\"><span style = \"font-style:italic;\">1.5.4. Analyses of Safety Endpoints<\/span><\/div><div class = \"text-block\">Analyses of safety endpoints are not included in the interim analysis for this study.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"#94EBFF","section_duration":0,"critical":[{"id":12,"title":"Critical step","icon":"CriticalIcon"}],"critical_id":null,"duration":0},{"id":935747,"guid":"D40D9180909411EAAAA2CDB4FD66F056","previous_id":935731,"previous_guid":"16C38A00909211EAAAA2CDB4FD66F056","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"D7E91ED6E5884FAFB744C7C0D1DAC725","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"16BB3EE6DBDC476684A20A9D2EB348D9","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Stopping Rule<\/span><\/div><div class = \"text-block\">This study does not have a formal stopping rule that is based on statistical testing.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":"","section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":935749,"guid":"E5D03AD0909411EAAAA2CDB4FD66F056","previous_id":935747,"previous_guid":"D40D9180909411EAAAA2CDB4FD66F056","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"F8223BFBFD9F44D4A4E1BCCC7A098510","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"6A26DCC12FDC462681F251377AB42197","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">Handling of Missing Data<\/span><\/div><div class = \"text-block\">Subjects with missing primary outcome data will be excluded from the interim analysis.<\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":null,"section_duration":0,"critical":null,"critical_id":null,"duration":0},{"id":935752,"guid":"1E863460909511EAAAA2CDB4FD66F056","previous_id":935749,"previous_guid":"E5D03AD0909411EAAAA2CDB4FD66F056","modified_on":0,"protocol_id":0,"components":[{"id":1054723,"guid":"64C5AB9907534DE08C2E7124B492F694","order_id":1,"type_id":6,"title":"Section","source":{"title":""}},{"id":1054724,"guid":"5441BA2B8F604782966EFBF494907355","order_id":1,"type_id":1,"title":"description","source":{"description":"<div class = \"text-blocks\"><div class = \"text-block\"><span style = \"font-weight:bold;\">References<\/span><span>    <\/span><\/div><div class = \"text-block\"><span>Angeli, P., Gin\u00e8s, P., Wong, F., Bernardi, M., Boyer, T.D., Gerbes, A., Moreau, R., Jalan, R., Sarin, S.K., Piano, S., et al. (2015). Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut <\/span><span style = \"font-style:italic;\">64<\/span><span>, 531\u2013537.<\/span><\/div><div class = \"text-block\"><span>Kellum, J.A., Lameire, N., Aspelin, P., Barsoum, R.S., Burdmann, E.A., Goldstein, S.L., Herzog, C.A., Joannidis, M., Kribben, A., Levey, A.S., et al. (2012). Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements <\/span><span style = \"font-style:italic;\">2<\/span><span>, 1\u2013138.<\/span><\/div><div class = \"text-block\"><span>Kellum, J.A., Zarbock, A., and Nadim, M.K. (2017). What endpoints should be used for clinical studies in acute kidney injury? Intensive Care Medicine <\/span><span style = \"font-style:italic;\">43<\/span><span>, 901\u2013903.<\/span><\/div><\/div>"}}],"cases":[],"data":null,"html":null,"section":null,"section_color":null,"section_duration":0,"critical":null,"critical_id":null,"duration":0}],"document":null,"materials":[],"description":"<div class = \"text-blocks\"><div class = \"text-block\">Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies). Patients who experience AKI after liver transplantation have higher mortality, increased graft loss, longer hospital and intensive care unit stays, and more progression to chronic kidney disease compared with those who do not. In this study, half of the participants will have their body temperature cooled to slightly lower than normal (mild hypothermia) for a portion of the liver transplant operation, while the other half will have their body temperature maintained at normal. The study will evaluate if mild hypothermia protects from AKI during liver transplantation.<\/div><div class = \"text-block\">This study is a single-blinded, randomized controlled trial of mild hypothermia during liver transplantation to provide protection from AKI. Participants will be randomized to normothermia (36.5-37.5 \u00b0C) versus mild hypothermia (34-35 \u00b0C) during a portion of the liver transplant operation. The protocol is based on preliminary data from rodent models showing that hypothermia protects the kidneys from ischemia-reperfusion injury, as well as studies in deceased organ donors showing that cooling improves post-transplant organ function. Temperature will be maintained with standard techniques plus a minimally-invasive esophageal cooling device that is approved by the U.S. Food and Drug Administration. The investigators hypothesize that mild hypothermia will reduce the incidence and severity of AKI after LTx. Standard surrogates (e.g., change in serum creatinine, need for initiation of dialysis) and biomarkers will be used to assess the severity of kidney injury.<\/div><\/div>","changed_on":1588892371}